Population PK Modeling and Target Attainment Simulations to Support Dosing of Ceftaroline Fosamil in Pediatric Patients With Acute Bacterial Skin and Skin Structure Infections and Community-Acquired Bacterial Pneumonia
| Autor: | Todd Riccobene, Timothy J. Carrothers, Shampa Das, Tatiana Khariton, James Li, John S. Bradley, William Knebel, Alena Jandourek |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
Pharmacology medicine.medical_specialty education.field_of_study business.industry 030106 microbiology Population Bacterial pneumonia medicine.disease_cause medicine.disease 03 medical and health sciences Pharmacokinetics Staphylococcus aureus Internal medicine Pharmacodynamics Streptococcus pneumoniae medicine Ceftaroline fosamil Pharmacology (medical) Dosing business education medicine.drug |
| Zdroj: | The Journal of Clinical Pharmacology. 57:345-355 |
| ISSN: | 0091-2700 |
| DOI: | 10.1002/jcph.809 |
| Popis: | Ceftaroline, the active form of the prodrug ceftaroline fosamil, is approved for use in adults with community-acquired bacterial pneumonia (CABP) or acute bacterial skin and skin structure infections (ABSSSI) in the United States and for similar indications in Europe. Pharmacokinetic (PK) data from 5 pediatric (birth to MIC) for pediatric dose regimens. With dose regimens of 8 mg/kg every 8 hours (q8h) in children aged 2 months to 90% of children were predicted to achieve a target of 36% fT>MIC at an MIC of 2 mg/L, and >97% were predicted to achieve 44% fT>MIC at an MIC of 1 mg/L. Thus, high PK/pharmacodynamic target attainment would be maintained in children for targets associated with 1-log kill of Staphylococcus aureus and Streptococcus pneumoniae. The predicted ceftaroline exposures for these dose regimens were similar to those in adults given 600 mg q12h ceftaroline fosamil. This work contributed to the approval of dose regimens for children aged 2 months to |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text